Full-Time

Quality Assurance Specialist

Confirmed live in the last 24 hours

Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals

501-1,000 employees

Develops RNAi-based therapies for diseases

Compensation Overview

$65k - $80k/yr

Mid

Fitchburg, WI, USA

The job is located in Verona, WI, and applicants must have authorization to work in the US.

Category
QA & Testing
Quality Assurance
Required Skills
Word/Pages/Docs
Excel/Numbers/Sheets
Requirements
  • Bachelor's degree in a science field
  • At least three years of experience working in a regulated environment with preference to quality assurance auditing and/or raw material experience
  • Working knowledge of drug GMP regulations, as well as ICH/FDA guidance documents
  • Competent knowledge of and ability to use Microsoft Word and Excel and Smartsheet
  • Ability to follow company procedures, work instructions, and policies
  • Work in a safe manner; properly handle materials and chemicals
  • Excellent attention to detail and organizational skills
  • Ability to multi-task and prioritize work tasks with minimal supervision
  • Excellent interpersonal, verbal, and written communication skills
Responsibilities
  • Interact with representatives from other departments, including QC and Analytical Development, to obtain the necessary information for review of documentation
  • Review and approve analytical testing data and final reports from internal and external sources
  • Assist with investigations and deviations, as appropriate
  • Organization and control of project related documentation
  • Perform release of controlled documents such as logbooks and other forms, as well as a final quality review on completed forms, weight set verifications, label reconciliations
  • Scan and upload executed documents to the EDMS, properly categorize within the system, and route for verification/approval
  • Maintain knowledge of current compliance expectations and regulations pertaining to drug development
  • Review and perform QA disposition of all incoming raw materials intended for GMP manufacturing, including proper labeling of packaging/containers (Released, Quarantine, Rejected) according to Arrowhead Quality Procedures
  • Additional duties as assigned
Desired Qualifications
  • Previous experience with quality systems supporting drug-device combination products per 21 CFR Part 3 and medical devices QSR per 21 CFR Part 820/ISO 13485
  • Prior experience with use of an electronic document management system in a regulated environment
Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals

View

Arrowhead Pharmaceuticals develops medicines aimed at treating severe diseases by targeting and silencing the genes responsible for them. The company uses RNA interference (RNAi), a natural process that reduces the expression of specific genes, to achieve effective treatment outcomes. This method allows for significant and lasting reductions in the activity of harmful genes, which can help manage or potentially reverse diseases like cystic fibrosis and hepatitis B. Arrowhead stands out from its competitors by focusing specifically on RNAi-based therapies and leveraging a wide range of RNA chemistries and delivery methods. The company aims to meet unmet medical needs by providing new treatment options for genetic disorders, generating revenue through partnerships, licensing agreements, and future sales of approved therapies.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Pasadena, California

Founded

2004

Simplify Jobs

Simplify's Take

What believers are saying

  • Arrowhead's collaboration with Sarepta includes a $500M upfront payment for RNA drug development.
  • Positive Phase 2 data for plozasiran boosts Arrowhead's credibility in treating hypertriglyceridemia.
  • Strategic financing with Sixth Street provides capital to advance Arrowhead's research pipeline.

What critics are saying

  • Increased competition from companies like Alnylam may impact Arrowhead's market share.
  • Potential regulatory scrutiny could delay Arrowhead's clinical trials for RNAi therapies.
  • Reliance on strategic financing may lead to increased debt obligations for Arrowhead.

What makes Arrowhead Pharmaceuticals unique

  • Arrowhead uses RNAi to target and silence disease-causing genes effectively.
  • The company has a broad portfolio of RNA chemistries for diverse therapeutic applications.
  • Arrowhead's strategic partnerships enhance its capabilities in developing innovative RNAi therapies.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

Paid Vacation

Paid Sick Leave

Company News

BioSpace
Apr 15th, 2025
Arrowhead Pharmaceuticals Appoints Daniel Apel as Chief Financial Officer

Mr. Apel joins the company from Walgreens Boots Alliance, where he served as Global Head of Financial Planning and Analysis from 2019 through 2024.

PharmaData
Mar 1st, 2025
Arrowhead Pharmaceuticals Launches FCS Patient Resources on Rare Disease Day

Arrowhead Pharmaceuticals launches FCS patient resources on Rare Disease Day.

Business Wire
Feb 28th, 2025
Arrowhead Pharmaceuticals Launches on Rare Disease Day New Patient-Centric Resources for Those Affected by Familial Chylomicronemia Syndrome (FCS)

New Patient Resource Hub: Arrowhead expands its We'll Get There Soon campaign with the launch of a dedicated patient website, providing education, tools, and support for those living with FCS and extremely high triglycerides

World Pharmaceuticals
Nov 29th, 2024
Dev4All and Pharmaseed enter commercial partnership for preclinical R&D

Recently, Arrowhead Pharmaceuticals and Sarepta Therapeutics signed a global licensing and collaboration agreement to develop clinical and preclinical programmes.

BioSpace
Nov 26th, 2024
Sarepta Aims Up to $10B at Arrowhead to Diversify Pipeline With RNA Drugs

Sarepta Therapeutics is putting massive biobucks on the line to work on RNA drugs with Arrowhead, paying out $500 million upfront to find new treatments for rare genetic diseases of the muscle, central nervous system and lung.